European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. The compound was designed to address issues such as payload toxicity seen in first-generation ADC therapies, according to Zai Lab.

Chemotherapy 97

Chemotherapy Compounding Immunity Immunization 97

European Pharmaceutical Review

OCTOBER 19, 2023

With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? What do you envision the future of radiopharmaceuticals to be like?

Chemotherapy 105

Chemotherapy Compounding Immunity Immunization 105

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI.

Immunity 105

Immunity Immunization Chemotherapy Compounding 105

Pharmaceutical Technology

AUGUST 12, 2022

Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. billion in 2021 and is forecast to reach $2.4

Immunity 52

Immunity Immunization Chemotherapy Compounding 52

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections.

Dosage 59

Dosage Chemotherapy Compounding Immunity 59

The Thyroid Pharmacist

NOVEMBER 4, 2022

While the human body (via the liver and kidneys) can produce up to 4 g/day of inositol, it has been found that the overly processed, high glucose (and low fiber) Western diets that many people follow, only provide about 1 g/day of the compound. (7). Brain Behav Immun. Recommended Dosage and Precautions. 2012;26(4):559-563. 2012.01.006.

Diabetes 98

Diabetes Dosage Compounding Immunity 98

RX Note

AUGUST 4, 2023

You may also refresh knowledge of clinical pharmacokinetics , total parenteral nutrition or chemotherapy before entering the relevant rotations. You should be at least familiar with insulin and inhalers counselling before entering ward, inpatient or outpatient. What to do if I did not know the answer to questions from patients or doctors?

Hospitals 52

Hospitals Inpatient Community Pharmacies Dosage 52